Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension and dose titration

25 May 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Hung-Yu Chang

Cheng-Hsin General Hospital, Taipei (Taiwan)

56 More presentations in this session

Presentation thumbnail

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Doctor L. Borg (Msida, MT)

Presentation thumbnail

Sacubitril valsartan, a multicentric experience

Mr F. Cortes (Sevilla, ES)

Presentation thumbnail

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Professor B. Kanazirev (Varna, BG)

Abstract Slides

Presentation thumbnail

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Associate Professor C. Hsu (Taipei, TW)

Abstract Slides

Presentation thumbnail

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Doctor C. Hsieh (Taipei, TW)

Access the full session

Session thumbnail

Poster Session 3 - Chronic Heart Failure – Treatment

The Event

Heart Failure 2019

25 May - 28 May 2019

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources